ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,827.04
      -1.54%
      US Tech 100
      20,287.60
      0.00%
      Dow Jones
      41,938.45
      -1.63%
      Brent Oil
      80.425
      -0.24%
      Bitcoin
      93,116.98
      -1.45%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE

      6. Hikma Pharmaceuticals Plc (HIK) Quote

      Hikma Pharmaceuticals Plc

      Hikma Pharmaceuticals Plc (HIK)

      Haiki
      Hikari Tsushin Inc
      2,000.00
      -22.00
      ( -1.09% )
      Updated: 03:07:00
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      2,000.00
      Bid
      1,998.00
      Ask
      2,004.00
      Volume
      7,168
      1,999.00 Day's Range 2,062.00
      1,750.00 52 Week Range 2,165.00
      Market Cap
      4.438B
      Previous Close
      2,022.00
      Open
      2,062.00
      Last Trade
      44
      @
      2000
      (AT)
      Last Trade Time
      03:06:18
      Financial Volume
      145,615p
      VWAP
      2,031.4642
      Average Volume (3m)
      431,328
      Shares Outstanding
      221,886,453
      Dividend Yield
      4.80%
      PE Ratio
      23.37
      Earnings Per Share (EPS)
      0.87
      Revenue
      2.88B
      Net Profit
      192M

      About Hikma Pharmaceuticals Plc

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.hikma.com
      Headquarters
      London, Gbr
      Founded
      -
      Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,022p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,750.00p to 2,165.00p.

      Hikma Pharmaceuticals currently has 221,886,453 shares outstanding. The market capitalization of Hikma Pharmaceuticals is £4.49 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 23.37.

      Ask ADVFN Intelligence (AI)

      HIK Latest News

      More News

      Hikma Pharmaceuticals Plc Director/PDMR Shareholding

      Hikma Pharmaceuticals Plc 23 December 2024   Hikma Pharmaceuticals PLC (the "Company") LONDON, 23 December 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI:...

      December 23 2024
      RNS Regulatory News

      Hikma Pharmaceuticals Plc Outcome of Audit Tender Process

      Hikma Pharmaceuticals Plc 07 November 2024   Hikma Pharmaceuticals PLC Outcome of Audit Tender Process   LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma...

      November 07 2024
      RNS Regulatory News

      Hikma Pharmaceuticals reiterates full-year guidance amid strong growth

      Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading t ...

      November 07 2024
      Alliance News

      Hikma Pharmaceuticals Plc Trading Statement

      Hikma Pharmaceuticals Plc 07 November 2024   Hikma continues strong strategic execution and reiterates guidance   London, 7 November 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the...

      November 07 2024
      RNS Regulatory News

      Hikma Pharmaceuticals Plc 2024 Annual General Meeting Update Statement

      Hikma Pharmaceuticals Plc 24 October 2024   Hikma Pharmaceuticals PLC 2024 Annual General Meeting Update Statement   LONDON, 24 October 2024 - Hikma Pharmaceuticals PLC ('Hikma' or 'the...

      October 24 2024
      RNS Regulatory News

      Hikma Pharmaceuticals Plc Block listing Interim Review

      Hikma Pharmaceuticals Plc 01 October 2024   Hikma Pharmaceuticals PLC Block Listing Six Monthly Return   Date: 1 October 2024   Name of applicant: Hikma Pharmaceuticals PLC Name of scheme:...

      October 01 2024
      RNS Regulatory News

      Hikma Pharmaceuticals Plc Director/PDMR Shareholding

      Hikma Pharmaceuticals Plc 24 September 2024   Hikma Pharmaceuticals PLC (the "Company")   LONDON, 24 September 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI:...

      September 24 2024
      RNS Regulatory News

      Hikma Pharmaceuticals completes acquisition of Xellia's FDF business

      Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form busine ...

      September 10 2024
      Alliance News
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1150.7556675062971985206619803241762025.0981874DE
      4633.252452245741937206618603344291975.7987919DE
      12-10-0.4975124378112010206617574313281903.98508841DE
      261819.950522264981819209017573822381921.36413512DE
      52804.166666666671920216517504126611917.37069221DE
      156-72-3.4749034749207222221174.55669431780.64184088DE
      26093.54.90427484921906.527661174.55948192024.8265086DE

      HIK - Frequently Asked Questions (FAQ)

      What is the current Hikma Pharmaceuticals share price?
      The current share price of Hikma Pharmaceuticals is 2,000.00p
      How many Hikma Pharmaceuticals shares are in issue?
      Hikma Pharmaceuticals has 221,886,453 shares in issue
      What is the market cap of Hikma Pharmaceuticals?
      The market capitalisation of Hikma Pharmaceuticals is GBP 4.49B
      What is the 1 year trading range for Hikma Pharmaceuticals share price?
      Hikma Pharmaceuticals has traded in the range of 1,750.00p to 2,165.00p during the past year
      What is the PE ratio of Hikma Pharmaceuticals?
      The price to earnings ratio of Hikma Pharmaceuticals is 23.37
      What is the cash to sales ratio of Hikma Pharmaceuticals?
      The cash to sales ratio of Hikma Pharmaceuticals is 1.56
      What is the reporting currency for Hikma Pharmaceuticals?
      Hikma Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Hikma Pharmaceuticals?
      The latest annual turnover of Hikma Pharmaceuticals is USD 2.88B
      What is the latest annual profit for Hikma Pharmaceuticals?
      The latest annual profit of Hikma Pharmaceuticals is USD 192M
      What is the registered address of Hikma Pharmaceuticals?
      The registered address for Hikma Pharmaceuticals is 1 NEW BURLINGTON PLACE, LONDON, W1S 2HR
      What is the Hikma Pharmaceuticals website address?
      The website address for Hikma Pharmaceuticals is www.hikma.com
      Which industry sector does Hikma Pharmaceuticals operate in?
      Hikma Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TM1Technology Minerals Plc
      0.15p
      (25.00%)
      		11.48M
      MASTMast Energy Developments Plc
      0.205p
      (17.14%)
      		7.65M
      OMIOrosur Mining Inc
      8.25p
      (17.02%)
      		180.01k
      NFXNuformix Plc
      0.07p
      (16.67%)
      		15.44M
      ZIOCZanaga Iron Ore Company Limited
      8.66p
      (9.76%)
      		22.07k
      VRSVersarien Plc
      0.03p
      (-16.67%)
      		134.87k
      THSTharisa Plc
      55.50p
      (-14.62%)
      		44.18k
      EYEEagle Eye Solutions Group Plc
      405.00p
      (-14.01%)
      		9.29k
      ZENZenith Energy Ltd.
      5.50p
      (-10.57%)
      		245.98k
      4GBL4global Plc
      45.50p
      (-9.00%)
      		95
      TRPTower Resources Plc
      0.0405p
      (2.53%)
      		95.59M
      CPXCap-xx Limited
      0.155p
      (-4.62%)
      		32.99M
      DGIDg Innovate Plc
      0.0185p
      (-7.50%)
      		23.47M
      NFXNuformix Plc
      0.07p
      (16.67%)
      		15.44M
      ORCPOracle Power Plc
      0.019p
      (0.00%)
      		13.53M

      Discussion

      View Full Feed
      DiamondHealer95 DiamondHealer95 7 minutes ago
      I mean Kim said once they hit 1.5 metric tons they're open for business and they're about halfway there so..... You're a genius! Congrats on the business. I also run one with 100% positive feedback over 22 years so I get the perspective🤪

      Also, in my Arby's voice "I have the
      KBLB
      DiamondHealer95 DiamondHealer95 10 minutes ago
      We've invested similarly
      KBLB
      sunspotter sunspotter 22 minutes ago
      Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.
      VPLM
      Flobewan Flobewan 32 minutes ago
      Marc loved your ides
      tinojax tinojax 33 minutes ago
      I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........
      PLUG
      mrfence mrfence 36 minutes ago
      Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
      [yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]
      FMCC FNMA
      IVRT IVRT 52 minutes ago
      In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25
      BMXI
      DewDiligence DewDiligence 52 minutes ago
      GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

      https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

      ENTA
      DewDiligence DewDiligence 53 minutes ago
      GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

      https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

      Guido2 Guido2 54 minutes ago
      This is DUE DILIGENCE! Thank you Free Fannie.

      https://x.com/freefannie/status/1878655047715991552?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ
      FNMA
      StockItOut StockItOut 1 hour ago
      That Xeriant PR excellently written with bullshit:

      ""After successfully completing 75% of the demanding NFPA 286 test," meaning = "after failing the NFPA 286 test by missing 25% of the approval target testing requirement,"

      "the Company used the data to make several key
      XERI
      gitreal gitreal 1 hour ago
      You were actually partially right....BMXI has filed some SEC documents, some necessary (Form 1-A), some unnecessary (Form 4). And they do summarize a lot of the stuff that I think are fabrications....their production, mining operations, etc. Time will tell, but I think a lot of it (and probably
      BMXI
      RichieBoy RichieBoy 1 hour ago
      Jim wrote a blurb about seeking more US business.

      Help you out any? 🤨
      AFFU
      DesktopDR DesktopDR 1 hour ago
      Any news or updates?
      VPLM
      Tahoe2468 Tahoe2468 1 hour ago
      .0915 by Thursday....... 
      KRTL
      skitahoe skitahoe 1 hour ago
      Remember GBM was redefined during the trial, thus some who were treated then had other forms of brain cancer. I believe the least we'll see in our label is brain cancer. Certainly GBM may be the deadliest of them, but treatment should work in all of them.

      According to Google, GBM ha
      NWBO
      fuagf fuagf 1 hour ago
      You are right about the crafty, evil, smart. Authoritarian methods have been in full view
      in capturing America. While we work to do the right things they plot to capture the lot.
      facts_matter14 facts_matter14 1 hour ago
      If there weren’t suckers born every minute, there wouldn’t be POSRMX bag holders down as much as 99%, and there sure as hell wouldn’t be anybody believing there is a pipeline of products.






      .
      SRMX
      StockItOut StockItOut 1 hour ago
      Your "closer" keeps getting extended. Then again extended. Then again extended. -- Consider that end. Now expired, horizon end now reached, and the view clarifies and we see it to be your desperation from years ago ongoing still, to pump this at any expense, where you attempt to instill FOMO to hold
      XERI
      fuagf fuagf 1 hour ago
      He would smother any question with words.
      Shawonsarker84 Shawonsarker84 1 hour ago
      $HMBL Sorry HMBL investors. XTIA now broke the record 2.7B share volume traded before the reverse split.



      https://x.com/shawonsarker84/status/1878696680088019193?t=rZlhkn2Jos4vWKxxQgXGfA&s=19
      HMBL XTIA
      chen1992 chen1992 1 hour ago
      https://www.energy.senate.gov/hearings/2025/1/hearing-to-consider-the-nomination-of-mr-chris-wright-to-be-secretary-of-energy

      https://www.commerce.senate.gov/2025/1/full-committee-nomination-hearing_2#:~:text=U.S.%20Senator%20Ted%20Cruz%20(R,Wednesday%2C%20January%2015%2C%20
      TGLO

      Your Recent History

      LSE
      HIK
      Hikma Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads